- The U.S. Patent Office issues a notice of allowance for a claim covering "core architectural aspects of engineered Transcription Activator-Like Effectors."
- Sangamo BioSciences (SGMO) says it expects the architectures "to be broadly adopted and become the industry standard."
- The technology can be used to edit gene sequences when used with the company's "proprietary engineered FokI nucleases, or DNA cutting domains." (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 7:14AM)
at Benzinga.com (Jan 12, 2015)
at CNBC.com (Jan 9, 2015)
at Benzinga.com (Dec 17, 2014)
at CNBC.com (Sep 9, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs